Empagliflozin With Add-On Linagliptin Effective After Metformin Failure
After metformin failure, sequential treatment escalation with empagliflozin and linagliptin is an effective diabetes treatment option due to additive effects on postprandial glucose control, according to a study published online in Diabetes, Obesity and Metabolism.
Thomas Forst, MD, from Johannes Gutenberg University in Mainz, Germany, and colleagues conducted an open-label trial (treatment period [TP] 1) in which 44 patients with type 2 diabetes received 25 mg empagliflozin for one month. In TP 2, patients were randomized to a double-blind add-on therapy with linagliptin 5 mg or placebo for another month. A standardized liquid meal test and an intravenous glucose challenge were used to assess alpha- and beta-cell function.